Perspective Therapeutics Inc CATX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs
-
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors
-
Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium
-
Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026
-
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
-
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026
-
Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results
-
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results
Trading Information
- Previous Close Price
- $2.26
- Day Range
- $1.58–2.40
- 52-Week Range
- $1.58–6.16
- Bid/Ask
- $1.64 / $1.65
- Shares Outstanding
- 114.15M
- Market Cap
- $183.78M
- Volume/Avg
- 6M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 166
Valuation
|
Metric
|
CATX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.57 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CATX
|
|---|---|
Quick Ratio | 6.49 |
Current Ratio | 6.61 |
Interest Coverage | −410.60 |
Quick Ratio
CATX
Profitability
|
Metric
|
CATX
|
|---|---|
Return on Assets (Normalized) | −31.81% |
Return on Equity (Normalized) | −38.44% |
Return on Invested Capital (Normalized) | −40.72% |
Return on Assets
CATX
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|r%ST@kg | LOCK|c^@?c | $179B | |||
| Medtronic PLC
MDT
| LOCK|k<KPx@B | LOCK|l<&%q | $122B | |||
| Stryker Corp
SYK
| LOCK|G%h$QxJ | LOCK|qNn | $118B | |||
| Boston Scientific Corp
BSX
| LOCK|M%VbQLj | LOCK|$RJgv | $66B | |||
| Edwards Lifesciences Corp
EW
| LOCK|jjPPFGK | LOCK|#>@q | $51B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|F!^wq<? | LOCK|!N? | $32B | |||
| DexCom Inc
DXCM
| LOCK|sz#jcB< | LOCK|N^@@X | $29B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|h! | LOCK|mFK | $26B | |||
| Steris PLC
STE
| LOCK|Jkgzp% | LOCK|v&?k | $23B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|f!^jPzfZ | LOCK|&v | $19B |
United States